IMCD (ENXTAM:IMCD) is in focus after Michelin ResiCare selected its European arm to distribute bio-based 5 HMF across the region, ahead of planned commercial production and rising interest in renewable platform chemicals.
See our latest analysis for IMCD.
The Michelin ResiCare agreement comes as IMCD’s share price sits at €88.52, with a 1 month share price return of 10.37% but a 1 year total shareholder return that is down 19.26%. This suggests that recent momentum contrasts with weaker long term results.
If this shift toward renewable chemicals has your attention, it could be a good moment to broaden your search and check out 106 top founder-led companies
For IMCD, the recent rebound sits against multi year returns that are still weak, so it is not obvious whether pricing now reflects a shift in fundamentals or just changing sentiment. The next question is how that balance shows up in the valuation.
Most Popular Narrative: 21.3% Undervalued
Compared to IMCD’s last close at €88.52, the most followed valuation narrative points to a fair value anchor of €112.50 based on long term cash flow expectations.
IMCD's strategic expansion into high-growth and resilient end-markets (pharma, food & nutrition, personal care) through both organic efforts and targeted M&A increases exposure to industries with strong, recurring demand fundamentals, which can support sustainable revenue and margin expansion as macro uncertainty fades.
The company's ongoing investment in digitalization (for example, sales assistant tool, omnichannel strategy) is expected to drive greater operational efficiency, customer stickiness, and scalability, potentially leading to improved cost structure and higher net margins over the medium to long term.
The fair value story for IMCD hangs on a specific mix of revenue growth, margin uplift and a richer future earnings multiple. Curious which assumptions really move that €112.50 figure.
Result: Fair Value of €112.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, IMCD still faces currency swings and acquisition risks that could pressure margins and cash generation, and may challenge the upside implied by the current narrative.
Find out about the key risks to this IMCD narrative.
Another View on IMCD’s Valuation
The 21.3% undervaluation figure for IMCD is based on long term cash flow assumptions. The preferred earnings multiple suggests a more demanding valuation. IMCD trades on a P/E of 24x, compared with a fair ratio of 19.8x, the Dutch peer average of 19.5x and the wider European Trade Distributors average of 19.4x. This indicates a richer valuation and less margin for error if the narrative does not play out as expected.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With IMCD, the story so far shows a mix of promise and concern, so it makes sense to look at both sides in detail and move quickly while information is fresh by weighing up the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond IMCD?
If IMCD has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to surface fresh opportunities that match your style and risk comfort.
- Target potential mispricings by reviewing carefully filtered opportunities in the 244 high quality undervalued stocks.
- Strengthen your income stream by checking companies that feature in the 442 dividend fortresses.
- Reduce surprises by focusing on resilient opportunities highlighted in the 302 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com